Telomir Pharmaceuticals Reported New Preclinical Cancer Data In Aggressive Human Prostate Cancer Cell Models Showing That Telomir-1 Inhibited DNA Hypermethylation Of CDKN2A, A Master Tumor Suppressor Gene-8K Filing
Benzinga·09/09/2025 11:49:38
Listen to the news
- CDKN2A plays a central role in controlling uninhibited cell growth and initiating programmed cell death, and its silencing is a well-established hallmark of cancer progression.
- Telomir-1 outperformed both Rapamycin and chemotherapy in inhibiting DNA hypermethylation of CDKN2A in the in vivo human prostate cancer model. These findings build upon previously reported data showing that Telomir-1 also resets DNA methylation of STAT1, a master immune regulator silenced in aggressive cancers.
- Together, the STAT1 and CDKN2A results demonstrate Telomir-1's ability to reset epigenetic silencing across multiple tumor suppressor pathways. This dual effect addresses two of cancer's most fundamental escape mechanisms: unchecked cell proliferation and immune evasion.
- Telomir is actively assessing Telomir-1 across multiple aggressive cancers beyond prostate, with additional studies underway. The company's pre-IND program is running in full gear, with CMC activities scaling up toward GMP production and IND-enabling studies ongoing as Telomir moves toward its first IND submission.